TY - JOUR
T1 - Serotype Replacement after Introduction of 10-Valent and 13-Valent Pneumococcal Conjugate Vaccines in 10 Countries, Europe
AU - Hanquet, Germaine
AU - Krizova, Pavla
AU - Dalby, Tina
AU - Ladhani, Shamez N.
AU - Nuorti, J. Pekka
AU - Danis, Kostas
AU - Mereckiene, Jolita
AU - Knol, Mirjam J.
AU - Winje, Brita A.
AU - Ciruela, Pilar
AU - de Miguel, Sara
AU - Portillo, Maria Eugenia
AU - MacDonald, Laura
AU - Morfeldt, Eva
AU - Kozakova, Jana
AU - Valentiner-Branth, Palle
AU - Fry, Norman K.
AU - Rinta-Kokko, Hanna
AU - Varon, Emmanuelle
AU - Corcoran, Mary
AU - van der Ende, Arie
AU - Vestrheim, Didrik F.
AU - Munoz-Almagro, Carmen
AU - Sanz, Juan-Carlos
AU - Castilla, Jesus
AU - Smith, Andrew
AU - Henriques-Normark, Birgitta
AU - Colzani, Edoardo
AU - Pastore-Celentano, Lucia
AU - Savulescu, Camelia
N1 - Funding Information: This study received funding from the European Centre for Disease Prevention and Control, the European Commission Horizon 2020, and the participating sites. Publisher Copyright: © 2022 Centers for Disease Control and Prevention (CDC). All rights reserved.
PY - 2022/1/1
Y1 - 2022/1/1
N2 - We evaluated invasive pneumococcal disease (IPD) during 8 years of infant pneumococcal conjugate vaccine (PCV) programs using 10-valent (PCV10) and 13-valent (PCV13) vaccines in 10 countries in Europe. IPD incidence declined during 2011-2014 but increased during 2015-2018 in all age groups. From the 7-valent PCV period to 2018, IPD incidence declined by 42% in children <5 years of age, 32% in persons 5-64 years of age, and 7% in persons >65 years of age; non-PCV13 serotype incidence increased by 111%, 63%, and 84%, respectively, for these groups. Trends were similar in countries using PCV13 or PCV10, despite different serotype distribution.Serotypes included in the 15- valent PCV represented one third of cases and those in the 20-valent PCVs two thirds of cases in children <5 years of age and in persons >65 years of age in 2018. Non-PCV13 serotype increases reduced the overall eff ect of childhood PCV10/PCV13 programs on IPD. New vaccines providing broader serotype protection are needed.
AB - We evaluated invasive pneumococcal disease (IPD) during 8 years of infant pneumococcal conjugate vaccine (PCV) programs using 10-valent (PCV10) and 13-valent (PCV13) vaccines in 10 countries in Europe. IPD incidence declined during 2011-2014 but increased during 2015-2018 in all age groups. From the 7-valent PCV period to 2018, IPD incidence declined by 42% in children <5 years of age, 32% in persons 5-64 years of age, and 7% in persons >65 years of age; non-PCV13 serotype incidence increased by 111%, 63%, and 84%, respectively, for these groups. Trends were similar in countries using PCV13 or PCV10, despite different serotype distribution.Serotypes included in the 15- valent PCV represented one third of cases and those in the 20-valent PCVs two thirds of cases in children <5 years of age and in persons >65 years of age in 2018. Non-PCV13 serotype increases reduced the overall eff ect of childhood PCV10/PCV13 programs on IPD. New vaccines providing broader serotype protection are needed.
UR - http://www.scopus.com/inward/record.url?scp=85121727482&partnerID=8YFLogxK
U2 - https://doi.org/10.3201/eid2801.210734
DO - https://doi.org/10.3201/eid2801.210734
M3 - Article
C2 - 34932457
SN - 1080-6040
VL - 28
SP - 127
EP - 138
JO - Emerging infectious diseases
JF - Emerging infectious diseases
IS - 1
ER -